Live Breaking News & Updates on ராமி லெவின்|Page 1

Stay updated with breaking news from ராமி லெவின். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Investegate |Saniona AB Announcements | Saniona AB: Saniona Hosts Research and Development (R&D) Day on Proprietary Ion Channel Drug Discovery Engine and Pipeline Programs

Saniona Launches New Video Series to Highlight the Impact of Prader-Willi Syndrome and ...


Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Saniona Launches New Video Series to Highlight the Impact of Prader-Willi Syndrome and .
Saniona ABMay 10, 2021 GMT
PRESS RELEASE
May 10, 2021
Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced its “Saniona’s Community Voices” video series, which will feature the voices of people living with rare diseases, their caregivers and their medical professionals. The series will launch during the month of May, which is both Prader-Willi syndrome (PWS) and Brain Tumor Awareness Month and will begin by spotlighting the impact of these conditions on patients and their families. ....

United States , United Kingdom , Marci Serota , Trista Morrison , Ulla Feldt Rasmussen , Saniona Youtube , Lynn Garrick , Tony Holland , University Of Cambridge , University Of Copenhagen , National University Hospital , Hungry For Solutions , Saniona Community , Brain Tumor Awareness Month , Rami Levin , Chief Executive Officer , Emeritus Professor , Registered Dietitian Nutritionist , Defeat Hypothalamic , Childhood Obesity , Medical Endocrinology , Chief Communications Officer , Nasdaq Stockholm Small Cap , Prader Willi Syndrome , Hypothalamic Obesity , ஒன்றுபட்டது மாநிலங்களில் ,

Saniona AB: Saniona publishes its year-end report for 2020


Saniona AB: Saniona publishes its year-end report for 2020
Revenue was SEK 8.2 M (7.2 M)
Operating loss was SEK -159.4 (-93.6 M)
Net loss was SEK -73.4 M (-68.8 M)
Earnings per share were SEK -1.79 (-2.67)
Diluted earnings per share were SEK -1.75 (-2.67)
Q4 2020 (Q4 2019 restated)
Revenue was SEK 1.6 M (0.0 M)
Operating loss was SEK -68.8 M (-28.2 M)
Net loss was SEK -45.6 M (-6.8 M)
Earnings per share were SEK -0.73 (-0.24)
Diluted earnings per share were SEK -0.73 (-0.24)
Business highlights in Q4 2020
Saniona achieved
positive top-line Phase 2 results from the open-label extension study of Tesomet in patients with HO. Patients treated with Tesomet for nearly one year (24 weeks in a double-blind trial followed by a 24-week open label extension) demonstrated statistically significant and clinically meaningful reductions in body weight and waist circumference, as well as improvements in glycemic control. Tesomet was well to ....

United States , United Kingdom , Trista Morrison , University Of Pennsylvania , Boehringer Ingelheim , Drug Administration , Treatment Research Center , Us Public Company Accounting Oversight Board , Investigational New Drug , Denelle Waynick , Chief Legal Officer , Kyle Haraldsen , Chief Technical Operations , Cadent Therapeutics , Risk Evaluation , Mitigation Strategy , Rami Levin , Chief Executive Officer , Company Accounting Oversight Board , Chief Communications Officer , Nasdaq Stockholm Small , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , ட்ரிஸ்டா மோரிசன் , பல்கலைக்கழகம் ஆஃப் பென்சில்வேனியா , போஹெரிங்கர் இஂகல்‌ஹைம் ,

Saniona publishes its year-end report for 2020


Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Saniona publishes its year-end report for 2020
Saniona ABMarch 17, 2021 GMT
PRESS RELEASE
Revenue was SEK 8.2 M (7.2 M)
Operating loss was SEK -159.4 (-93.6 M)
Net loss was SEK -73.4 M (-68.8 M)
Earnings per share were SEK -1.79 (-2.67)
Diluted earnings per share were SEK -1.75 (-2.67)
Q4 2020 (Q4 2019 restated)
Revenue was SEK 1.6 M (0.0 M)
Operating loss was SEK -68.8 M (-28.2 M)
Net loss was SEK -45.6 M (-6.8 M)
Earnings per share were SEK -0.73 (-0.24)
Diluted earnings per share were SEK -0.73 (-0.24) ....

United States , Trista Morrison , University Of Pennsylvania , Boehringer Ingelheim , Drug Administration , Treatment Research Center , Us Public Company Accounting Oversight Board , Investigational New Drug , Denelle Waynick , Chief Legal Officer , Kyle Haraldsen , Chief Technical Operations , Cadent Therapeutics , Risk Evaluation , Mitigation Strategy , Rami Levin , Chief Executive Officer , Company Accounting Oversight Board , Chief Communications Officer , Nasdaq Stockholm Small Cap , Child And Teen Health , Drug Trials , Products And Services , Health Care Industry , Corporate News , North America ,